FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570675753> ?p ?o ?g. }

• W2570675753 endingPage "S409" @default.
• W2570675753 startingPage "S408" @default.
• W2570675753 abstract "Small cell lung cancer (SCLC) that has progressed after 1st line therapy has few effective treatments and no new class of approved therapies in over 20 years. Paired tumor-normal exome and transcriptome sequencing efficiency, coverage, cost, and analytics has improved over the last decade and has begun to be applied in the clinic. In this prospective study, we used genome-wide strexome (exome+structural variation) plus whole transcriptome sequencing (NGS) to identify genomic events and associated expression changes in advanced SCLC and attempt to prescribe systemic therapy based on the results (NCT02297087, study was funded by SU2C). After informed consent a prospective fresh frozen tumor biopsy was obtained. Germline DNA was extracted from PBMC and reference normal tissue RNA was obtained commercially. Strexome and RNA-seq libraries were prepped and NGS, data analysis, and reporting were performed in a CLIA-certified CAP accredited environment. The study completed its accrual goal of 12 evaluable patients. There was one screen failure due to anticipated inadequate sample yield because of tumor location. The cohort included 10 women, median age was 56.5 years and had 3 never smokers. All patients received prior platinum-based chemotherapy and were receiving >1st line systemic treatment while awaiting NGS results. The minimum tumor content for successful NGS was 20%. The median turnaround time from sample collection to report was 27 days (range 21-38). Average strexome coverage was 420X (tumor), 200X (germline), with an average of 277 million RNA reads generated for tumors. All patients had 32 clinically actionable targets identified (associated with a commercially available, FDA-approved drug by predefined rules), median 4 targets (range 2-8). Three patients received treatment identified by NGS. One has continuing partial response by RECIST 1.1 >8 months on a clinical trial involving PD-1 inhibitor+irinotecan (MLH1 mutation); treatment linked to NGS was already initiated prior to the report becoming available. One is too early to evaluate on olaparib (PARP1 mutation), and one had disease progression on dasatinib (KIT overexpression) as best overall response. One patient has not yet received NGS recommended therapy, and the remaining 8 evaluable patients had clinical deterioration or died before NGS recommended therapy was initiated. SCLC after 1st line therapy tends to have more rapid progression and deterioration making NGS application for systemic therapy challenging. Either applying NGS earlier in the earlier stages of disease course or further improvements in turnaround time may better address these challenges." @default.
• W2570675753 created "2017-01-13" @default.
• W2570675753 creator A5003576514 @default.
• W2570675753 creator A5018960036 @default.
• W2570675753 creator A5074460206 @default.
• W2570675753 creator A5076157472 @default.
• W2570675753 creator A5080669646 @default.
• W2570675753 creator A5080927178 @default.
• W2570675753 creator A5082779886 @default.
• W2570675753 creator A5087945532 @default.
• W2570675753 creator A5090712632 @default.
• W2570675753 date "2017-01-01" @default.
• W2570675753 modified "2023-09-26" @default.
• W2570675753 title "MA11.10 Prospective Study of Genome-Wide Strexome and Transcriptome Profiling in Patients with Small Cell Lung Cancer Progressing after 1st Line Therapy" @default.
• W2570675753 doi "https://doi.org/10.1016/j.jtho.2016.11.468" @default.
• W2570675753 hasPublicationYear "2017" @default.
• W2570675753 type Work @default.
• W2570675753 sameAs 2570675753 @default.
• W2570675753 citedByCount "0" @default.
• W2570675753 crossrefType "journal-article" @default.
• W2570675753 hasAuthorship W2570675753A5003576514 @default.
• W2570675753 hasAuthorship W2570675753A5018960036 @default.
• W2570675753 hasAuthorship W2570675753A5074460206 @default.
• W2570675753 hasAuthorship W2570675753A5076157472 @default.
• W2570675753 hasAuthorship W2570675753A5080669646 @default.
• W2570675753 hasAuthorship W2570675753A5080927178 @default.
• W2570675753 hasAuthorship W2570675753A5082779886 @default.
• W2570675753 hasAuthorship W2570675753A5087945532 @default.
• W2570675753 hasAuthorship W2570675753A5090712632 @default.
• W2570675753 hasBestOaLocation W25706757531 @default.
• W2570675753 hasConcept C104317684 @default.
• W2570675753 hasConcept C10590036 @default.
• W2570675753 hasConcept C126322002 @default.
• W2570675753 hasConcept C127716648 @default.
• W2570675753 hasConcept C143998085 @default.
• W2570675753 hasConcept C150194340 @default.
• W2570675753 hasConcept C162317418 @default.
• W2570675753 hasConcept C16671776 @default.
• W2570675753 hasConcept C188816634 @default.
• W2570675753 hasConcept C2776256026 @default.
• W2570675753 hasConcept C54355233 @default.
• W2570675753 hasConcept C71924100 @default.
• W2570675753 hasConcept C86803240 @default.
• W2570675753 hasConceptScore W2570675753C104317684 @default.
• W2570675753 hasConceptScore W2570675753C10590036 @default.
• W2570675753 hasConceptScore W2570675753C126322002 @default.
• W2570675753 hasConceptScore W2570675753C127716648 @default.
• W2570675753 hasConceptScore W2570675753C143998085 @default.
• W2570675753 hasConceptScore W2570675753C150194340 @default.
• W2570675753 hasConceptScore W2570675753C162317418 @default.
• W2570675753 hasConceptScore W2570675753C16671776 @default.
• W2570675753 hasConceptScore W2570675753C188816634 @default.
• W2570675753 hasConceptScore W2570675753C2776256026 @default.
• W2570675753 hasConceptScore W2570675753C54355233 @default.
• W2570675753 hasConceptScore W2570675753C71924100 @default.
• W2570675753 hasConceptScore W2570675753C86803240 @default.
• W2570675753 hasIssue "1" @default.
• W2570675753 hasLocation W25706757531 @default.
• W2570675753 hasOpenAccess W2570675753 @default.
• W2570675753 hasPrimaryLocation W25706757531 @default.
• W2570675753 hasRelatedWork W1953186510 @default.
• W2570675753 hasRelatedWork W2109785031 @default.
• W2570675753 hasRelatedWork W2338872041 @default.
• W2570675753 hasRelatedWork W2561928803 @default.
• W2570675753 hasRelatedWork W2580725728 @default.
• W2570675753 hasRelatedWork W2951733423 @default.
• W2570675753 hasRelatedWork W3167348758 @default.
• W2570675753 hasRelatedWork W3183702008 @default.
• W2570675753 hasRelatedWork W3213685426 @default.
• W2570675753 hasRelatedWork W4290546020 @default.
• W2570675753 hasVolume "12" @default.
• W2570675753 isParatext "false" @default.
• W2570675753 isRetracted "false" @default.
• W2570675753 magId "2570675753" @default.
• W2570675753 workType "article" @default.